Skip to main content
. 2019 Dec 11;14(1):159–179. doi: 10.1002/1878-0261.12595

Figure 1.

Figure 1

Expression of RSK isoforms in gliomas of different grades and recurrence. (A) RSK1, (B) RSK2, and (C) RSK3 protein levels and (G) P(S380)‐RSK levels in astrocytomas and nontumoral brain (NB) from the ACCCC cohort are expressed as HSCORE. The dashed line indicates the 3rd quartile for all the samples. (D) RSK1, (E) RSK2, and (F) RSK3 protein levels and (H) P(S380)‐RSK levels in samples bearing IDH1R132H mutation. The wild‐type samples (empty circles) were not considered for statistics calculation. (I) Analysis of RPPA data (TCGA) for P(T359/S363)‐RSK1 antibody in LGG (grades II and III) and GBM (grade IV). P(T359/S363)‐RSK1 levels were compared for grade II, grade III, and grade IV (GBM). The number of samples in each grade is indicated in parentheses. (J) IHC reactions for RSK1 in matched samples of LGG and the corresponding GBM recurrence from three different patients. The grade for the corresponding LGG is indicated. Scale bars: 50 μm. (K–N) Quantification of (K) RSK1, (L) RSK2, and (M) RSK3 protein levels and (N) P(S380)‐RSK levels for the cases shown in (J). The P‐value for a paired sample t‐test is indicated.